Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.
By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross USD 1 Billion in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.
While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.
Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.
Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.
Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals preferhormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.
That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.
The endometriosis treatment market size is estimated to cross USD3.55 Billion by 2032.
The endometriosis treatment market is likely to record a value of USD 1.30 Billion in 2022.
Europe is likely to lead the endometriosis treatment market.
Explore Therapy Area Insights
View Reports
Endometriosis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
